Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog – Page 11222

Synthetic biology meets senolytics at Lifespan.io

We are developing tools to help researchers accurately target and remove dysfunctional cells in the body that have entered a state called “senescence”, and thereby assist in restoring it to youthful functionality. Please subscribe, share, and fund our campaign today! ►Campaign Link: https://www.lifespan.io/campaigns/cellage-targeting-senescen…c-biology/ ►Subscribe: https://www.youtube.com/user/LifespanIO?sub_confirmation=1

Our society has never aged more rapidly – one of the most visible symptoms of the changing demographics is the exponential increase in the incidence of age-related diseases, including cancer, cardiovascular diseases and osteoarthritis. Not only does aging have a negative effect on the quality of life among the elderly but it also causes a significant financial strain on both private and public sectors. As the proportion of older people is increasing so is health care spending. According to a WHO analysis, the annual number of new cancer cases is projected to rise to 17 million by 2020, and reach 27 million by 2030. Similar trends are clearly visible in other age-related diseases such as cardiovascular disease. Few effective treatments addressing these challenges are currently available and most of them focus on a single disease rather than adopting a more holistic approach to aging.

Continue reading “CellAge: Senescent Cell Targeting Technology Video” | >

Dr. Aubrey de Grey from the SENS Research Foundation was kind enough to talk in support of CellAge and their campaign on Lifespan.io

We are developing tools to help researchers accurately target and remove dysfunctional cells in the body that have entered a state called “senescence”, and thereby assist in restoring it to youthful functionality. Please subscribe, share, and fund our campaign today! ►Campaign Link: https://www.lifespan.io/campaigns/cellage-targeting-senescen…c-biology/ ►Subscribe: https://www.youtube.com/user/LifespanIO?sub_confirmation=1

Our society has never aged more rapidly – one of the most visible symptoms of the changing demographics is the exponential increase in the incidence of age-related diseases, including cancer, cardiovascular diseases and osteoarthritis. Not only does aging have a negative effect on the quality of life among the elderly but it also causes a significant financial strain on both private and public sectors. As the proportion of older people is increasing so is health care spending. According to a WHO analysis, the annual number of new cancer cases is projected to rise to 17 million by 2020, and reach 27 million by 2030. Similar trends are clearly visible in other age-related diseases such as cardiovascular disease. Few effective treatments addressing these challenges are currently available and most of them focus on a single disease rather than adopting a more holistic approach to aging.

Continue reading “CellAge: Dr. Aubrey de Grey Endorsement Video” | >

Cellular senescence is a complicated process but here it is explained in a simple infographic. The removal of senescent cells (senolytics) is a very hot topic right now and it represents the arrival of the first of the SENS therapies.

CellAge is one of the companies engaged in senolytic research and they are running a campaign on Lifespan.io if you would like to learn more about them.

https://www.lifespan.io/campaigns/cellage-targeting-senescen…c-biology/

Lifespan.io / Life Extension Advocacy Foundation

Continue reading “Senescent cells accumulate with age and gradually poison their neighboring cells and secrete signals that shut down your stem cells and reduce your ability to regenerate tissue” | >

Lilly announced today that CYRAMZA® (ramucirumab) has been approved by the Singapore Health Sciences Authority to treat people with advanced gastric cancer, whose cancer has progressed after prior chemotherapy. First country in ASEAN to approve the new biologic therapy that extends survival in patients with advanced stomach cancer after prior chemotherapy

CYRAMZA® (ramucirumab) is now available to Singaporeans living with advanced gastric cancer. The drug gained approval by Singapore’s Health Science’s Authority (HSA) earlier this year, marking the first regulatory approval in ASEAN. CYRAMZA is already available to patients in Japan, Korea, Taiwan and Hong Kong.

Read more

Are you an avid supporter of aging research and a keen longevity activist?
The Biogerontology Research Foundation is offering select summer internships for talented individuals. You’d join a passionate and supportive team in researching diagnostic, prognostic, and therapeutic strategies; advising a panel of investors in developing a roadmap to promote longevity science and related technologies across the globe.

The advertised positions are 3 month internships, with the possibility of continuing afterwards. Free accommodation will be provided for in London, alongside a negotiable salary.

The Biogerontology Research Foundation is a UK based think tank dedicated to aging research and accelerating its application worldwide.

Apply to: [email protected]

Are you an avid supporter of aging research and a keen longevity activist?

The Biogerontology Research Foundation is offering select summer internships for talented individuals. You €™d join a passionate and supportive team in researching diagnostic, prognostic, and therapeutic strategies; advising a panel of investors in developing a roadmap to promote longevity science and related technologies across the globe.

Read more

For the past four decades, the electronics industry has been driven by what is called “Moore’s Law,” which is not a law but more an axiom or observation. Effectively, it suggests that the electronic devices double in speed and capability about every two years. And indeed, every year tech companies come up with new, faster, smarter and better gadgets.

Specifically, Moore’s Law, as articulated by Intel cofounder Gordon Moore, is that “The number of transistors incorporated in a chip will approximately double every 24 months.” Transistors, tiny electrical switches, are the fundamental unit that drives all the electronic gadgets we can think of. As they get smaller, they also get faster and consume less electricity to operate.

In the technology world, one of the biggest questions of the 21st century is: How small can we make transistors? If there is a limit to how tiny they can get, we might reach a point at which we can no longer continue to make smaller, more powerful, more efficient devices. It’s an industry with more than US$200 billion in annual revenue in the U.S. alone. Might it stop growing?

Read more

India is all set to test its Agni-V intercontinental ballistic missile (ICBM), capable of striking even the northernmost parts of China, in its final operational configuration from Odisha. Notedly, this will be fourth and the final test of nuclear-capable Agni-V. It will be tested for its full range, before Strategic Forces Command begins its user trials.

The country’s most formidable nuclear missile till now since it brings the whole of China and much more within its strike envelope, the three-stage Agni-V was earlier tested in “an open configuration” in April 2012 and September 2013.

The third test on Jan 30 2015 was done from a hermetically-sealed canister mounted on a Tatra launcher truck in “a deliverable configuration”.

Read more